Home Top Movers Epizyme, Inc. (EPZM) Stock Experiences Volatility Following Disclosure of Q1 2021 Financial...

Epizyme, Inc. (EPZM) Stock Experiences Volatility Following Disclosure of Q1 2021 Financial Reports

Epizyme, Inc. (EPZM) stock prices were down by 9.44% as of the market closing on May 6th 2021, bringing the price per share down to USD$6.81 at the end of the trading day. Subsequent current-market fluctuations have seen the stock rally by 20%, bringing it up to USD$8.17.

Financial Reports Indicate Strong Growth

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

The first quarter of the fiscal year 2021 saw TAZVERIK generate net product revenue of USD$6.2 million, with March breaking the record of the highest level of commercial demand since launch. Commercial demand for bottles grew 31% in the first quarter of 2021 as compared to the fourth quarter of 2020, with revenue having grown by 37% in that time. Q1 2021 also reported a 38% increase in new prescribing accounts over Q4 2020.

Promising Early Trial Results

The Phase 1b/3 confirmatory study in relapsed/refractory Follicular Lymphoma patients is designed to evaluate the effectiveness of a combination of TAZVERIK and R2 as treatment. Preliminary safety and activity data were shown to exhibit encouraging initial treatment responses in each cohort the 13 patients were divided amongst. Any adverse effects reported were in line with forecasts based on the respective safety profile of each individual agent.

Ahead of Schedule

Following discussions with the U.S. FDA, Phase 3 protocol has been amended to include a second interim analysis upon the occurrence of 65% of progression free survival events. This change facilitates access to efficacy data ahead of schedule and could result in a stoppage of the study should the predefined treatment effect be realized.

Expansion of Patient Cohorts

Furthermore, the Phase 1b segment of the Epizyme study has been expanded to include a minimum of 15 patients in the 600 and 800 mg BID cohorts to aid the selection for the Phase 3 dose. With enrollment nearing completion for the two cohorts, patients are currently being evaluated for the required follow-up of three months before the initiation of the Phase 3 randomization portion of the trial.

Progress in Several Trials

Designed to evaluate the effectiveness of TAZVERIK and Rituxan in patients with relapsed/refractory FL, EZPM’s Phase 2 trial EZH-1401 is actively enrolling and is on schedule. Enrollment is also continuing in the Lymphoma Study Association (LYSA) trial. In the study evaluating the effectiveness of TAZVERIK and doxorubicin as a front-line treatment for Epithelioid Sarcoma patients, enrollment has been completed in the Phase 1b safety run-in portion of the trial.

Future Outlook for EPZM

With consistently progressing developments across studies for a varied pipeline of treatments, the company is striving towards increased commercialization. Current and potential investors are hopeful for continued success in trials that will usher in a future of significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Here’s why Soligenix, Inc. (SNGX) stock is Popping High today

Soligenix, Inc. (SNGX) stock gained Pediatric Investigation Plan (PIP) waiver for HyBryte™ (SGX301 or hypericin) by European Medicines Agency (EMA) after which the SNGX...

Clover Health Investments Corp. (CLOV) stock rises during pre-market. Let’s find out why?

Clover Health Investments Corp. (NASDAQ: CLOV) stock declined by 23.61% at last close while the CLOV stock price gains by 5.73% in the pre-market...

GameStop Inc. (GME) stock plunged during after-hour session. Here’s the update

GameStop Inc. (NASDAQ: GME) stock gained by 0.85% at the last close while the GME stock price declines by 5.21% in the after-hours session....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam